Investigating a genetic variant's role in Alzheimer's disease.
Official title: Pathogenic Role of APP E590D in Alzheimer’s Disease.
Funded at Case Western Reserve University · NIH-11159819 · Data updated 2026-11-12
This study is looking at a specific gene change that may lead to more harmful proteins in the brains of people with Alzheimer's, using human brain cells and mice to learn how it affects brain health and could help find new treatments.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | August 15, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $161,000 |
| NIH project number | 5R03AG084948-02 |
| Project ID | NIH-11159819 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a genetic predisposition to Alzheimer's disease, particularly those with the APP E590D variant.
✕Less likely to help
Patients without the APP E590D variant or those with other forms of dementia may not benefit from this research.
What this research studies
This research focuses on the APP E590D variant, which has been linked to increased production of amyloid-beta (Aβ) in Alzheimer's disease. By using human neurons derived from patients' fibroblasts, the study aims to understand how this variant affects Aβ pathology and neuronal health. The researchers will also create a mouse model to further explore the effects of this variant on Alzheimer's-related processes. This approach could provide insights into the mechanisms of Alzheimer's disease and potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for diagnosing and treating Alzheimer's disease.
How similar studies have gone: Previous research has shown success in understanding the role of genetic variants in Alzheimer's disease, making this approach promising.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Liu, Tian — Case Western Reserve University
- Study coordinator: Liu, Tian
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.